<DOC>
	<DOCNO>NCT01521312</DOCNO>
	<brief_summary>Glucose ACCES study explore acute long term ( 12-week treatment ) effect saxagliptin patient impair glucose tolerance fasting standardise breakfast . The investigation perform : - glycemic parameter - cardiovascular parameter</brief_summary>
	<brief_title>ACute Chronic Effects Saxagliptin</brief_title>
	<detailed_description>The aim pilot study compare patient impair glucose tolerance effect saxagliptin versus placebo : ( ) glucose metabolism ( ii ) vago-sympathetic activity , arterial stiffness endothelial function . A total 36 patient recruit department Endocrinology-Diabetology-Nutrition Jean VERDIER hospital , AP-HP , Bondy , France . The measurement perform morning 1 ) time randomisation ( Acute ACCES study ) 2 ) 11-14 week begin saxagliptin placebo ( Chronic ACCES study ) . We evaluate fast hour standardize breakfast : ( ) biological metabolic parameter . Furthermore , oral glucose tolerance test perform end study . ( ii ) non-invasive device arterial stiffness ( Sphygmocor® ) , endothelial function ( ENDOPAT 2000® ) , cutaneous microcirculation ( laser doppler Perimed ®.PF 5010 ) cardiac autonomic function ( task force monitor® ) .</detailed_description>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Social security affiliation Persons without TUTORSHIP freely agree participate study Age 18 70 year Impaired glucose tolerance diagnose previous month . Exclusion criterion : Pregnancy Breast feed Diabetes No contraception Body Mass Index &gt; 45 kg/m² Arterial blood pressure &gt; 160/110 mmHg Creatinine clearance &lt; 60 ml/min Severe hepatocellular insufficiency Chronic respiratory disease Anaemia ( Hemoglobin &lt; 10 g/dl ) Peripheral arterial occlusive disease Heart failure Cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Impaired glucose tolerance</keyword>
	<keyword>Saxagliptin</keyword>
	<keyword>Cardiovascular risk integrator</keyword>
	<keyword>Vago-sympathetic activity</keyword>
	<keyword>Arterial stiffness</keyword>
	<keyword>Endothelial function</keyword>
</DOC>